225 related articles for article (PubMed ID: 35390143)
1. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Tashakori M; Kadia T; Loghavi S; Daver N; Kanagal-Shamanna R; Pierce S; Sui D; Wei P; Khodakarami F; Tang Z; Routbort M; Bivins CA; Jabbour EJ; Medeiros LJ; Bhalla K; Kantarjian HM; Ravandi F; Khoury JD
Blood; 2022 Jul; 140(1):58-72. PubMed ID: 35390143
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
3. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
[TBL] [Abstract][Full Text] [Related]
4. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
5. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of TP53-mutated myeloid malignancies.
Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
[TBL] [Abstract][Full Text] [Related]
7. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
8. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Yildiz M; Saiya-Cork K; Shedden K; Malek SN
Clin Cancer Res; 2015 May; 21(9):2045-56. PubMed ID: 25652455
[TBL] [Abstract][Full Text] [Related]
9. Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia.
Meena JP; Pathak N; Gupta AK; Bakhshi S; Gupta R; Makkar H; Seth R
Leuk Res; 2022 Nov; 122():106954. PubMed ID: 36162216
[TBL] [Abstract][Full Text] [Related]
10. Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E; Gerstung M; Bullinger L; Gaidzik VI; Paschka P; Roberts ND; Potter NE; Heuser M; Thol F; Bolli N; Gundem G; Van Loo P; Martincorena I; Ganly P; Mudie L; McLaren S; O'Meara S; Raine K; Jones DR; Teague JW; Butler AP; Greaves MF; Ganser A; Döhner K; Schlenk RF; Döhner H; Campbell PJ
N Engl J Med; 2016 Jun; 374(23):2209-2221. PubMed ID: 27276561
[TBL] [Abstract][Full Text] [Related]
11. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.
Fernandez-Mercado M; Yip BH; Pellagatti A; Davies C; Larrayoz MJ; Kondo T; Pérez C; Killick S; McDonald EJ; Odero MD; Agirre X; Prósper F; Calasanz MJ; Wainscoat JS; Boultwood J
PLoS One; 2012; 7(8):e42334. PubMed ID: 22912701
[TBL] [Abstract][Full Text] [Related]
12. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
[TBL] [Abstract][Full Text] [Related]
14. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
[No Abstract] [Full Text] [Related]
16. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
18. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
20. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
